Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck atozet (ezetimibe/atorvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2020
453
Period ended Dec 31, 2020
Change on a year earlier
+15.9%
391 in FY2019
History
5 years
Since FY2016
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Atozet (ezetimibe/atorvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | 453 | +15.9% | Form 10-K (filed 2021-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 391 | +12.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 347 | +54.2% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 225 | +54.1% | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 146 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up atozet (ezetimibe/atorvastatin, legacy pre-organon spin-off) — worldwide sales ($m)
Cite this data
StockData. (2026). Merck Atozet (ezetimibe/atorvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_atozet
See every metric in the Merck KPI table. Data updated Oct 26, 2026.